SEC Form 4 · accession 0001209191-17-064177

GLOBUS MEDICAL INC · GMED

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

David D Davidar

Director

Period of report

Dec 4, 2017

Accepted (ET)

Dec 6, 2017 · 4:11 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001237831

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Class A Common Stock	Dec 4, 2017	M	18,461	$4.88	A	752,236	D
Class A Common Stock^F1	Dec 4, 2017	S	18,461	$40.655	D	733,775	D
Class A Common Stock	Dec 4, 2017	M	18,461	$11.86	A	752,236	D
Class A Common Stock^F2	Dec 4, 2017	S	18,461	$40.655	D	733,775	D
Class A Common Stock	Dec 4, 2017	M	18,461	$10.66	A	752,236	D
Class A Common Stock^F3	Dec 4, 2017	S	18,461	$40.655	D	733,775	D
Class A Common Stock^F4	holding	—	—		—	225,967	I	By Davidar Family Irrevocable Trust U/A 8/6/09

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Stock Option (Right to Buy Class A Common Stock)^F5	$4.88	Dec 4, 2017	M	18,461	D	—	Aug 6, 2019	Class A Common Stock	18,461	D
Stock Option (Right to Buy Class A Common Stock)^F6	$11.86	Dec 4, 2017	M	18,461	D	—	Jun 16, 2020	Class A Common Stock	18,461	D
Stock Option (Right to Buy Class A Common Stock)^F7	$10.66	Dec 4, 2017	M	18,461	D	—	Oct 27, 2021	Class A Common Stock	18,461	D

Explanation of responses

F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.37 to $40.82, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.37 to $40.82, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.37 to $40.82, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
F4These shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse is trustee of the trust.
F5These options were granted on August 6, 2009, and vested over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2010, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
F6These options were granted on June 16, 2010, and vested over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2011, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.
F7These options were granted on October 27, 2011, and vested over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2012, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.